Aug 22, 2018

Motley Fool ‘Extreme Opportunities’ Advisor Dr Anirban Mahanti covers Starpharma’s 2018 Financial Year Results

Motley Fool ‘Extreme Opportunities’ Advisor Dr Anirban Mahanti covers Starpharma’s 2018 Financial Year Results

Dr Anirban Mahanti, Advisor at Motley Fool writes that FY18 was a “hugely transformative year for Starpharma”, noting the Company’s key milestones including its “smart licensing agreements” and “potentially game-changing pipeline of drugs”. Originally published on Motley Fool and republished with permission. Read the full article here

 This contains certain forward-looking statements.